Nov. 14 at 1:39 PM
@outlawinvestor1
Good morning.
$DCTH CEO filed a Form 4 this morning showing he purchased 11,500 DCTH shares @
$8.53/share.
DCTH has an approved therapy called a Hepzato Kit that treats certain mUM type liver cancers. The TAM is considered, more or less, the same as Kimmtrak from IMCR. Sales were doing well until they missed last quarter & actually fell from Q2
FYI DCTH was almost down for the count 3 years ago in the months leading up to approval. A private equity group purchased DCTH shares with all sorts of warrant coverage. When DCTH peaked at last May at
$18 they showed the highest shareholder ROI (to date at the time) of any comm'l-stage oncology focused bio.
It's my experience the private equity folks prefer to exit within 3 years max. They closed this financing late March 2023 so 3 years is nearing soon.
Just an idea for you. I otherwise share only because I know you appreciate CEO purchases.
